Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 58%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc has demonstrated a robust market presence, evidenced by the significant increase in Chromium reaction volumes, which indicates continued demand for its integrated solutions despite ongoing pricing pressures. The company's consumable sales are projected to grow substantially at a rate of 5-19 times per platform by 2027, outpacing instrument revenue growth, highlighting strong potential for future profitability. As a leading provider of life science technologies, 10x Genomics is well-positioned to capitalize on its innovative product offerings amid a competitive marketplace, further strengthening its financial outlook.

Bears say

10x Genomics Inc. has experienced a contraction in 2024, marked by double-digit pricing pressure impacting revenues and a stagnation in volume growth, with expectations for recovery not anticipated until 2027. The company also reported weaker than expected results for Q4, including an earnings per share (EPS) miss and a full-year revenue outlook that fell below analyst predictions. Cumulatively, these setbacks have contributed to a significant decline in stock value, with a drop of over 90% since its peak in 2021.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 58% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.